特应性皮炎瘙痒机制的研究进展

doi:10.35541/cjd.20201117

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (4): 357-361.doi: 10.35541/cjd.20201117

特应性皮炎瘙痒机制的研究进展

王傲姚煦

中国医学科学院、北京协和医学院皮肤病医院过敏与风湿免疫科，南京 210042

收稿日期:2020-11-20 修回日期:2020-12-30 发布日期:2022-04-01
通讯作者: 姚煦 E-mail:dryao_xu@126.com
作者简介:作者希望12月底前定稿，电子版刊出 2021.11.17
基金资助:
国家自然科学基金（82073446）；江苏省社会发展重大项目（BE2020632）；南京市国家级临床医学中心培育计划项目（2019060001）；中国医学科学院医学与健康科技创新工程项目（2016-I2M-1-005）

Mechanisms of pruritus in atopic dermatitis

Wang Ao, Yao Xu

Department of Allergy and Rheumatology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2020-11-20 Revised:2020-12-30 Published:2022-04-01
Contact: Yao Xu E-mail:dryao_xu@126.com
Supported by:
National Natural Science Foundation of China （82073446）; The Key Project of Social Development in Jiangsu Province （BE2020632）; The Nanjing Incubation Program for National Clinical Research Center （2019060001）; CAMS Innovation Fund for Medical Sciences （2016-I2M-1-005）

摘要/Abstract

摘要： 【摘要】特应性皮炎（AD）瘙痒是一种典型的非组胺相关瘙痒，涉及复杂的神经传导通路。多种细胞因子和神经肽类物质以及皮肤屏障功能障碍、皮肤菌群失调也参与瘙痒信号的产生和传递。本综述聚焦近年AD瘙痒发病机制和治疗的主要研究进展。

关键词: 皮炎, 特应性, 瘙痒症, 细胞因子类, 皮肤屏障, 皮肤菌群

Abstract: 【Abstract】 Pruritus in atopic dermatitis （AD） is a typical non-histaminergic itch involving complex nerve pathways. A variety of cytokines and neuropeptides, skin barrier dysfunction and skin microbiome imbalance are also involved in the generation and transmission of itching-relatd signals. This review focuses on main research progress in the pathogenesis and treatment of pruritus in AD in recent years.

Key words: Dermatitis, atopic, Pruritus, Cytokines, Skin barrier, Skin microbiome

王傲姚煦. 特应性皮炎瘙痒机制的研究进展[J]. 中华皮肤科杂志, 2022,55(4):357-361. doi:10.35541/cjd.20201117

Wang Ao, Yao Xu. Mechanisms of pruritus in atopic dermatitis[J]. Chinese Journal of Dermatology, 2022, 55(4): 357-361.doi:10.35541/cjd.20201117

参考文献 54

［1］	Silverberg JI, Lei D, Yousaf M, et al. Association of atopic dermatitis severity with cognitive function in adults［J］. J Am Acad Dermatol, 2020,83（5）:1349⁃1359. doi: 10.1016/j.jaad. 2020.05.041.
［2］	Kong TS, Han TY, Lee JH, et al. Correlation between severity of atopic dermatitis and sleep quality in children and adults［J］. Ann Dermatol, 2016,28（3）:321⁃326. doi: 10.5021/ad.2016.28.3. 321.
［3］	Wang F, Kim BS. Itch: A Paradigm of neuroimmune crosstalk［J］. Immunity, 2020,52（5）:753⁃766. doi: 10.1016/j.immuni. 2020. 04.008.
［4］	Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:239⁃250. doi: 10.1111/jdv.15973.
［5］	Gouin O, L', Herondelle K, et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro⁃inflammatory response induced by their activation and their sensitization［J］. Protein Cell, 2017,8（9）:644⁃661. doi: 10.1007/s13238⁃017⁃0395⁃5.
［6］	Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron⁃specific GPCR Mrgprs are itch receptors mediating chloroquine⁃induced pruritus［J］. Cell, 2009,139（7）:1353⁃1365. doi: 10.1016/j.cell. 2009.11.034.
［7］	Azimi E, Reddy VB, Pereira P, et al. Substance P activates Mas⁃related G protein⁃coupled receptors to induce itch［J］. J Allergy Clin Immunol, 2017,140（2）:447⁃453.e3. doi: 10.1016/j.jaci.2016. 12.980.
［8］	Reddy VB, Lerner EA. Activation of mas⁃related G⁃protein⁃coupled receptors by the house dust mite cysteine protease Der p1 provides a new mechanism linking allergy and inflammation［J］. J Biol Chem, 2017,292（42）:17399⁃17406. doi: 10.1074/jbc.M117.787887.
［9］	Meixiong J, Vasavda C, Snyder SH, et al. MRGPRX4 is a G protein⁃coupled receptor activated by bile acids that may contribute to cholestatic pruritus［J］. Proc Natl Acad Sci U S A, 2019,116（21）:10525⁃10530. doi: 10.1073/pnas.1903316116.
［10］	Xing Y, Chen J, Hilley H, et al. Molecular signature of pruriceptive MrgprA3（+） neurons［J］. J Invest Dermatol, 2020,140（10）:2041⁃2050. doi: 10.1016/j.jid.2020.03.935.
［11］	Xie B, Li XY. Inflammatory mediators causing cutaneous chronic itch in some diseases via transient receptor potential channel subfamily V member 1 and subfamily A member 1［J］. J Dermatol, 2019,46（3）:177⁃185. doi: 10.1111/1346⁃8138.14749.
［12］	Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out?［J］. Clin Rev Allergy Immunol, 2016,51（3）:263⁃292. doi: 10.1007/s12016⁃ 015⁃8488⁃5.
［13］	Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch［J］. Cell, 2017,171（1）:217⁃228.e13. doi: 10.1016/j.cell.2017.08. 006.
［14］	Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC⁃14028 cream ⁃ a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild⁃to⁃moderate atopic dermatitis: a phase IIb randomized trial［J］. Br J Dermatol, 2019,180（5）:1030⁃1038. doi: 10.1111/bjd.17455.
［15］	Palkar R, Ongun S, Catich E, et al. Cooling relief of acute and chronic itch requires TRPM8 channels and neurons［J］. J Invest Dermatol, 2018,138（6）:1391⁃1399. doi: 10.1016/j.jid.2017.12. 025.
［16］	Zhao J, Munanairi A, Liu XY, et al. PAR2 mediates itch via TRPV3 signaling in keratinocytes［J］. J Invest Dermatol, 2020,140（8）:1524⁃1532. doi: 10.1016/j.jid.2020.01.012.
［17］	Seo SH, Kim S, Kim SE, et al. Enhanced thermal sensitivity of TRPV3 in keratinocytes underlies heat⁃induced pruritogen release and pruritus in atopic dermatitis［J］. J Invest Dermatol, 2020,140（11）:2199⁃2209.e6. doi: 10.1016/j.jid.2020.02.028.
［18］	Topal FA, Zuberbier T, Makris MP, et al. The role of IL⁃17, IL⁃23 and IL⁃31, IL⁃33 in allergic skin diseases［J］. Curr Opin Allergy Clin Immunol, 2020,20（4）:367⁃373. doi: 10.1097/ACI. 0000000000000658.
［19］	Bilsborough J, Leung DY, Maurer M, et al. IL⁃31 is associated with cutaneous lymphocyte antigen⁃positive skin homing T cells in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2006,117（2）:418⁃425. doi: 10.1016/j.jaci.2005.10.046.
［20］	Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: Involvement of TRPV1 and TRPA1［J］. J Allergy Clin Immunol, 2014,133（2）:448⁃460. doi: 10.1016/j.jaci.2013.10.048.
［21］	Wilson SR, Thé L, Batia LM, et al. The epithelial cell⁃derived atopic dermatitis cytokine TSLP activates neurons to induce itch［J］. Cell, 2013,155（2）:285⁃295. doi: 10.1016/j.cell.2013.08. 057.
［22］	Petra AI, Tsilioni I, Taracanova A, et al. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E［J］. Allergy Asthma Proc, 2018,39（2）:153⁃160. doi: 10.2500/aap.2018.38. 4105.
［23］	Liu B, Tai Y, Achanta S, et al. IL⁃33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy［J］. Proc Natl Acad Sci U S A, 2016,113（47）:E7572⁃7572E7579. doi: 10.1073/pnas.1606608113.
［24］	Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL⁃31⁃induced atopic dermatitis［J］. J Allergy Clin Immunol, 2018,141（5）:1677⁃1689.e8. doi: 10.1016/j.jaci.2017.12.1002.
［25］	Feld M, Garcia R, Buddenkotte J, et al. The pruritus⁃ and TH2⁃associated cytokine IL⁃31 promotes growth of sensory nerves［J］. J Allergy Clin Immunol, 2016,138（2）:500⁃508.e24. doi: 10. 1016/j.jaci.2016.02.020.
［26］	Oh MH, Oh SY, Lu J, et al. TRPA1⁃dependent pruritus in IL⁃13⁃induced chronic atopic dermatitis［J］. J Immunol, 2013,191（11）:5371⁃5382. doi: 10.4049/jimmunol.1300300.
［27］	Singh B, Jegga AG, Shanmukhappa KS, et al. IL⁃31⁃driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin⁃barrier function［J］. PLoS One, 2016,11（8）:e0161877［2020⁃09⁃03］. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0161877. doi: 10.1371/journal.pone.016 1877.
［28］	Ryu WI, Lee H, Bae HC, et al. IL⁃33 down⁃regulates CLDN1 expression through the ERK/STAT3 pathway in keratinocytes［J］. J Dermatol Sci, 2018,90（3）:313⁃322. doi: 10.1016/j.jdermsci.2018.02.017.
［29］	Ding W, Stohl LL, Wagner JA, et al. Calcitonin gene⁃related peptide biases Langerhans cells toward Th2⁃type immunity［J］. J Immunol, 2008,181（9）:6020⁃6026. doi: 10.4049/jimmunol.181. 9.6020.
［30］	Meng J, Chen W, Wang J. Interventions in the B⁃type natriuretic peptide signalling pathway as a means of controlling chronic itch［J］. Br J Pharmacol, 2020,177（5）:1025⁃1040. doi: 10.1111/bph.14952.
［31］	Kiguchi N, Sukhtankar DD, Ding H, et al. Spinal functions of b⁃type natriuretic peptide, gastrin⁃releasing peptide, and their cognate receptors for regulating itch in mice［J］. J Pharmacol Exp Ther, 2016,356（3）:596⁃603. doi: 10.1124/jpet.115.229997.
［32］	Buhl T, Ikoma A, Kempkes C, et al. Protease⁃activated receptor⁃2 regulates neuro⁃epidermal communication in atopic dermatitis［J］. Front Immunol, 2020,11:1740. doi: 10.3389/fimmu.2020. 01740.
［33］	Yosipovitch G, Misery L, Proksch E, et al. Skin barrier damage and itch: review of mechanisms, topical management and future directions［J］. Acta Derm Venereol, 2019,99（13）:1201⁃1209. doi: 10.2340/00015555⁃3296.
［34］	Kido⁃Nakahara M, Wang B, Ohno F, et al. Inhibition of mite⁃induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan［J］. Allergy, 2021,76（1）:291⁃301. doi: 10.1111/all.14451.
［35］	Imai Y, Yasuda K, Sakaguchi Y, et al. Immediate⁃type contact hypersensitivity is reduced in interleukin⁃33 knockout mice［J］. J Dermatol Sci, 2014,74（2）:159⁃161. doi: 10.1016/j.jdermsci. 2014.01.009.
［36］	Talagas M, Lebonvallet N, Leschiera R, et al. Keratinocytes communicate with sensory neurons via synaptic⁃like contacts［J］. Ann Neurol, 2020,88（6）:1205⁃1219. doi: 10.1002/ana.25912.
［37］	Kim HS, Yosipovitch G. The skin microbiota and itch: is there a link?［J］. J Clin Med, 2020,9（4）. doi: 10.3390/jcm9041190.
［38］	Seiti Yamada Yoshikawa F, Feitosa de Lima J, Notomi Sato M, et al. Exploring the role of staphylococcus aureus toxins in atopic dermatitis［J］. Toxins （Basel）, 2019,11（6）. doi: 10.3390/toxins 11060321.
［39］	Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus δ⁃toxin induces allergic skin disease by activating mast cells［J］. Nature, 2013,503（7476）:397⁃401. doi: 10.1038/nature12655.
［40］	Chiu IM, Heesters BA, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation［J］. Nature, 2013,501（7465）:52⁃57. doi: 10.1038/nature12479.
［41］	Liu T, Xu ZZ, Park CK, et al. Toll⁃like receptor 7 mediates pruritus［J］. Nat Neurosci, 2010,13（12）:1460⁃1462. doi: 10.1038/ nn.2683.
［42］	Liu T, Berta T, Xu ZZ, et al. TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice［J］. J Clin Invest, 2012,122（6）:2195⁃2207. doi: 10.1172/JCI45414.
［43］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［44］	Nettis E, Ferrucci SM, Ortoncelli M, et al. Use of Dupilumab for 543 adult patients with moderate⁃to⁃severe atopic dermatitis: a multicenter, retrospective study［J］. J Investig Allergol Clin Immunol, 2020:0. doi: 10.18176/jiaci.0641.
［45］	Guttman⁃Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high⁃affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical Trial［J］. JAMA Dermatol, 2020,156（4）:411⁃420. doi: 10.1001/jamadermatol.2020.0079.
［46］	Wollenberg A, Blauvelt A, Guttman⁃Yassky E, et al. Tralokinumab for moderate⁃to⁃severe atopic dermatitis: results from two 52⁃week, randomized, double⁃blind, multicentre, placebo⁃controlled phase III trials （ECZTRA 1 and ECZTRA 2）［J］. Br J Dermatol, 2021,184（3）:437⁃449. doi: 10.1111/bjd.19574.
［47］	Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate⁃to⁃severe atopic dermatitis: results from the double⁃blind, randomized, multicentre, placebo⁃controlled phase III ECZTRA 3 trial［J］. Br J Dermatol, 2021,184（3）:450⁃463. doi: 10.1111/bjd.19573.
［48］	Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate⁃to⁃severe atopic dermatitis and severe pruritus［J］. J Allergy Clin Immunol, 2020,145（1）:173⁃182. doi: 10.1016/j.jaci.2019.08.013.
［49］	Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus［J］. N Engl J Med, 2020,383（2）:141⁃150. doi: 10.1056/NEJMoa1917006.
［50］	Guttman⁃Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16⁃week results from a randomized, placebo⁃controlled trial［J］. J Allergy Clin Immunol, 2020,145（3）:877⁃884. doi: 10.1016/j.jaci.2019.11.025.
［51］	Ferreira S, Guttman⁃Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib［J］. Am J Clin Dermatol, 2020,21（6）:783⁃798. doi: 10.1007/s40257⁃020⁃00548⁃6.
［52］	Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and an open⁃label, long⁃term extension study［J］. J Am Acad Dermatol, 2020,82（4）:823⁃831. doi: 10.1016/j.jaad.2019.12.015.
［53］	Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL⁃3893787 in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,143（5）:1830⁃1837.e4. doi: 10.1016/j.jaci.2018.07.047.
［54］	Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double⁃blind, placebo⁃controlled, multicenter, parallel⁃group study of a H4 R⁃antagonist （JNJ⁃39758979） in Japanese adults with moderate atopic dermatitis［J］. J Dermatol, 2015,42（2）:129⁃139. doi: 10.1111/1346⁃8138.12726.

[1]	宋晓婷刘擘陈玉迪赵作涛. 玫瑰痤疮的病理生理发病机制研究进展[J]. 中华皮肤科杂志, 2022, 55(5): 446-449.
[2]	孙晓丽李邻峰. 肥大细胞在变应性接触性皮炎发病中的作用进展[J]. 中华皮肤科杂志, 2022, 55(5): 449-451.
[3]	申晨陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445.
[4]	覃诗纯李梦杰陆晓云肖风丽. 特应性皮炎的转录组学研究进展[J]. 中华皮肤科杂志, 2022, 55(4): 365-369.
[5]	李巍尹慧彬. 特应性皮炎的部位异质性[J]. 中华皮肤科杂志, 2022, 55(4): 349-352.
[6]	李妍李明徐薇李邻峰. 【开放获取】凯普斯泰冷敷凝胶治疗成人轻中度特应性皮炎的随机双盲对照研究[J]. 中华皮肤科杂志, 2022, 55(4): 345-348.
[7]	何素玲田歆梁景耀邵蕾李俊龙黄琼霄刘玉梅王建琴. 重度特应性皮炎患者急性期和缓解期皮肤微生态研究[J]. 中华皮肤科杂志, 2022, 55(4): 329-336.
[8]	刘擘宋晓婷廖双璐于淼栾婷婷李若瑜赵作涛. 【开放获取】巴瑞替尼治疗中重度特应性皮炎的疗效和安全性观察[J]. 中华皮肤科杂志, 2022, 55(4): 304-307.
[9]	田晶梁源申春平赵牧童汪洋王珊焦磊马琳. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 299-303.
[10]	刘擘宋晓婷李若瑜赵作涛. 【开放获取】度普利尤单抗治疗特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(4): 295-298.
[11]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组. 【开放获取】特应性皮炎湿包疗法临床应用专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 289-294.
[12]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 281-288.
[13]	余愫郁天泽李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365.
[14]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 0(2): 20210694-e20210694.
[15]	黄雅馨, 何渊民, 黄书莉, 熊霞, 邓永琼. 血清几丁质酶3样蛋白1水平在寻常型天疱疮中的临床意义研究[J]. 中华皮肤科杂志, 2022, 0(2): 20210155-e20210155.

特应性皮炎瘙痒机制的研究进展

Mechanisms of pruritus in atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 54

相关文章 15

Metrics

本文评价

推荐阅读 10